Belantamab Mafodotin Elicits Responses in R/R Multiple Myeloma
A novel agent that targets B-cell maturation antigen achieved overall responses in more than 30% of heavily pretreated relapsed/refractory multiple myeloma patients; the drug is awaiting approval.